-
公开(公告)号：US11919836B2
公开(公告)日：2024-03-05
申请号：US16847988
申请日：2020-04-14
发明人： Sandeep Patil , Ron Bihovsky , Steven A Smith , Yuhua Ji , Valentino Stella , Daniel D. Long , Daniel Marquess
IPC分类号： C07C271/24 , A61K9/00 , A61K47/10 , A61K47/26 , A61K47/38 , A61K47/54 , A61K47/64 , C07C233/06 , C07C237/04 , C07C237/20 , C07C237/22 , C07C271/56 , C07K5/062
CPC分类号： C07C237/04 , A61K9/0019 , A61K9/0053 , A61K9/0095 , A61K47/10 , A61K47/26 , A61K47/38 , A61K47/542 , A61K47/64 , C07C233/06 , C07C237/20 , C07C237/22 , C07C271/24 , C07C271/56 , C07K5/06026 , C07K5/06052 , C07B2200/07 , C07C2602/42
摘要： Disclosed herein are pharmaceutical compositions comprising fencamfamine or fencamfamine related prodrug derivatives for targeted therapeutic applications and methods of synthesizing the compositions.
-
公开(公告)号：US20240067952A1
公开(公告)日：2024-02-29
申请号：US18243169
申请日：2023-09-07
申请人： YALE UNIVERSITY
IPC分类号： C12N9/96 , A61K45/06 , C07D493/10 , A61K31/165 , A61K31/365 , C07C279/12 , A61K47/60 , A61K47/54 , A61K31/352 , A61K38/05 , A61K38/48 , C07D491/107 , C07K5/062
CPC分类号： C12N9/96 , A61K45/06 , C07D493/10 , A61K31/165 , A61K31/365 , C07C279/12 , A61K47/60 , A61K47/54 , A61K31/352 , A61K38/05 , A61K38/482 , C07D491/107 , C07K5/06026
摘要： The present invention relates to chimeric (preferably, bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds preferably covalently bind to the urokinase receptor and recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and/or antibody-dependent cellular cytotoxicity (ADCC) against a large number and variety of cancers, thus providing cancer cell death and/or an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.
-
公开(公告)号：US20240025844A1
公开(公告)日：2024-01-25
申请号：US17929183
申请日：2022-09-01
申请人： Allergan, Inc.
IPC分类号： C07C275/30 , C07K5/062
CPC分类号： C07C275/30 , C07K5/06026
摘要： The present disclosure relates to phenyl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor (FPR), such as agonism of the FPR1 and/or FPR2 receptor, or selective agonism of the FPR1 receptor relative to the FPR2 receptor.
-
公开(公告)号：US20240002436A1
公开(公告)日：2024-01-04
申请号：US18036382
申请日：2021-11-15
申请人： Hofseth Biocare ASA
CPC分类号： C07K5/101 , C07K5/1016 , C07K5/1008 , C07K5/06026 , C07K5/06034 , C07K5/06078 , A61K38/00
摘要： Provided herein are methods for treating certain inflammatory and/or respiratory conditions, disorders and diseases in humans using compositions comprising lipopeptides, including microcolins. The compositions are orally administered. The humans suitable for such treatments include those largely resistant to medical and surgical interventions, such as steroid treatments. The compositions described herein have also been found to reduce cosinophil effector function.
-
5.发明公开公开(公告)号：US20230174577A1
公开(公告)日：2023-06-08
申请号：US17912647
申请日：2021-03-25
申请人： Nutrivert LLC
IPC分类号： C07K5/062 , A23K20/147
CPC分类号： C07K5/06026 , A23K20/147 , A61K38/00
摘要： Compositions of matter and methods to reduce inflammation in vertebrates and to promote growth and feed conversion in animals by administering an effective amount of a composition containing a mirror image molecule (enantiomer) of a lipophilic muramyl dipeptide (MDP) derivative that does not contain the N-acetylglucosamine moiety of MDP (i.e., a desmuramyl dipeptide).
-
公开(公告)号：US20180327472A1
公开(公告)日：2018-11-15
申请号：US15773273
申请日：2016-11-02
申请人： GENEXINE, INC.
发明人： Donghoon CHOI , Changyong EUN , Seong Hoon JEONG , Jun Yeul LIM
IPC分类号： C07K14/54
CPC分类号： C07K14/5418 , A61K9/08 , A61K38/2046 , A61K47/10 , A61K47/12 , A61K47/183 , A61K47/26 , C07K5/06026 , C07K5/0606 , C07K5/0806 , C07K5/081 , C07K5/1008 , C07K5/1013 , C07K7/06 , C07K14/54 , C07K2319/30
摘要： Provided is a pharmaceutical formulation comprising a modified IL-7 protein. More particularly, it comprises (a) a modified IL-7 fusion protein; (b) a basal buffer with a concentration of 10 to 50 mM; (c) a sugar with a concentration of 2.5 to 5 w/v %; and (d) a surfactant with a concentration of 0.05 to 6 w/v %. Such pharmaceutical formulation of a modified IL-7 fusion protein does not show aggregates formation, but shows protective effects on proteins under stress conditions such as oxidation or agitation, and thus can effectively be used for the treatment of a patient.
-
公开(公告)号：US10077287B2
公开(公告)日：2018-09-18
申请号：US14833422
申请日：2015-08-24
发明人： Heidi L. Perez , Donna Wei , Robert M. Borzilleri , Sanjeev Gangwar , Gretchen M. Schroeder , Heng Cheng , Robert J. Schmidt
CPC分类号： C07K5/06139 , A61K47/6803 , A61K47/6813 , A61K47/6817 , A61K47/6851 , A61K47/6889 , C07K5/06026 , C07K5/06034 , C07K5/06052 , C07K16/3038 , C07K16/3046
摘要： Tubulysin analogs of the formula (I) where R1, R2 R3, R4, R5, R6, R7, and Y are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
-
公开(公告)号：US10071164B2
公开(公告)日：2018-09-11
申请号：US14822309
申请日：2015-08-10
申请人： Yale University , Arvinas, Inc.
发明人： Andrew Crew , Craig Crews , Hanqing Dong , Eunhwa Ko , Jing Wang
IPC分类号： C07K5/062 , C07K5/097 , A61K45/06 , A61K31/427 , A61K31/426 , A61K38/00 , A61K47/48
CPC分类号： A61K47/55 , A61K31/426 , A61K31/427 , A61K38/00 , A61K45/06 , A61K47/545 , A61K47/551 , C07K5/06026 , C07K5/06034 , C07K5/06052 , C07K5/0821
摘要： The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
-
公开(公告)号：US10034912B2
公开(公告)日：2018-07-31
申请号：US15344813
申请日：2016-11-07
IPC分类号： A61K38/07 , A61K45/06 , A61K38/05 , A61K31/555
CPC分类号： A61K38/05 , A61K31/404 , A61K31/555 , A61K38/00 , A61K38/07 , A61K45/06 , A61N5/062 , A61N5/10 , C07D403/06 , C07D403/14 , C07K5/02 , C07K5/06 , C07K5/06026 , C12N5/0693 , C12N2500/46 , Y02P20/55
摘要： A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
-
公开(公告)号：US10000528B2
公开(公告)日：2018-06-19
申请号：US15722110
申请日：2017-10-02
申请人： Albireo AB
IPC分类号： A61K31/554 , A61K31/575 , A61K38/05 , C07K5/065 , C07K5/062 , A61K38/00
CPC分类号： C07K5/06078 , A61K31/55 , A61K31/554 , A61K31/575 , A61K38/00 , A61K38/05 , A61K2121/00 , C07K5/06026 , C07K5/0606
摘要： The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
-
-
-
-
-
-
-
-
-
搜索结果
1599 条记录 (耗时 0.041 秒)
